Saint Francis Health System

Allergy & Immunology Research Portfolio

The allergy and immunology research portfolio currently features a real-world study focused on chronic spontaneous urticaria. This study is designed to evaluate the effectiveness and safety of remibrutinib in routine clinical practice, helping researchers better understand how treatment decisions and outcomes may vary across a broader patient population.

The allergy and immunology research portfolio currently features a real-world study focused on chronic spontaneous urticaria. This study is designed to evaluate the effectiveness and safety of remibrutinib in routine clinical practice, helping researchers better understand how treatment decisions and outcomes may vary across a broader patient population.

REASSERT- NCT07358780 Prospective, non-interventional study in patients with CSU where the treatment decision prior enrolment has been made to either escalate current sgH1-AHs treatment or escalate/switch current treatment to remibrutinib. The primary aim of this study is to gather real-world effectiveness and safety data for remibrutinib, a new treatment option, covering a broader, real-world clinical practice population.

Study Details | NCT07358780 | Remibrutinib in Real-world Clinical Practice - a US Sub-study | ClinicalTrials.gov